Ocular TherapeutixFRA:0OT 51 Days Inventory is 249.03 as of Mar. 2026, which is 90% above its 10-year median of 131.33. GuruFocus rates FRA:0OT with a GF Score™ of 51/100 and a GF Value™ of €3.50 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 635 Biotechnology companies, Ocular Therapeutix ranks worse than 51.5% on this metric.
The historical rank and industry rank for Ocular Therapeutix's Days Inventory or its related term are showing as below:
FRA:0OT'
s Days Inventory Range Over the Past 10 Years
Min: 91.92 Med: 131.33 Max: 188.81
Current: 187.94
During the past 13 years, Ocular Therapeutix's highest Days Inventory was 188.81. The lowest was 91.92. And the median was 131.33.
FRA:0OT's Days Inventory is ranked worse than 51.5% of 635
companies
in the Biotechnology industry
Industry Median: 183.23
vs FRA:0OT: 187.94
Ocular Therapeutix's Days Inventory
increased
from Mar. 2025 (231.52) to Mar. 2026 (249.03).
It might indicate that Ocular Therapeutix's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ocular Therapeutix's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.37.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocular Therapeutix's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.34.
Ocular Therapeutix (FRA:0OT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ocular Therapeutix's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ocular Therapeutix's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Ocular Therapeutix Days Inventory Related Terms
Ocular Therapeutix Days Inventory Historical Data
* Premium members only.
The historical data trend for Ocular Therapeutix's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0OT vs NKTR, PVLA, GENB: Days Inventory Comparison
For the Biotechnology subindustry, Ocular Therapeutix's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Days Inventory distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix (FRA:0OT) has a Days Inventory of 249.03 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ocular Therapeutix and its competitors. This is 90% above median its historical median of 131.33. Over the past decade, Ocular Therapeutix's Days Inventory has ranged from 91.92 to 188.81. According to the industry distribution chart, Ocular Therapeutix ranks #327 out of 635 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Ocular Therapeutix's Days Inventory too high?
Ocular Therapeutix's current Days Inventory of 249.03 is 90% above median its 10-year median of 131.33. Over the past 10 years, this metric has ranged from a low of 91.92 to a high of 188.81. The Biotechnology industry median Days Inventory is 183.23. Ocular Therapeutix's value of 249.03 is 35.9% above this industry median. Based on the distribution chart, Ocular Therapeutix ranks #327 out of 635 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Days Inventory compare to NKTR and PVLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #327 out of 635 companies for Days Inventory. This places Ocular Therapeutix in the lower half of its industry. The industry median Days Inventory is 183.23. Ocular Therapeutix's value of 249.03 is 35.9% above this benchmark. Historically, Ocular Therapeutix's own Days Inventory has ranged from 91.92 to 188.81 over the past decade. While the company's 10-year median is 131.33 vs. the industry median of 183.23, Ocular Therapeutix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocular Therapeutix's current Days Inventory of 249.03 is 35.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Ocular Therapeutix and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocular Therapeutix's current Days Inventory is 249.03, which is 90% above median its own 10-year median of 131.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.50, compared to a current price of €8.25 — trading 135.7% above its estimated fair value. The current Days Inventory is 249.03, which is 90% above median its 10-year median of 131.33 and 35.9% above the Biotechnology industry median of 183.23. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Days Inventory is 249.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of €8.25 is trading 135.7% above its estimated GF Value™ of €3.50.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for FRA:0OT:
Days Inventory: 249.03 (90% above median its 10-year median of 131.33)
GF Value™: €3.50 vs. price of €8.25 (135.7% above fair value)
Industry Position: 35.9% above the Biotechnology median (#327 of 635)
No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score
Get the complete analysis for FRA:0OT
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0OT has been successfully added to your 
